Evidence map›Paper›PMID 31882969›Full record

ArticleScientific reports2019

Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma.

Kai-Hsiang Chang, Zhen-An Hwang, Ping-Ying Chang, Hsuan-Hwai Lin, Yu-Lueng Shih, Wei-Chou Chang, Guo-Shu Huang, Hsian-He Hsu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kai-Hsiang ChangDepartment of Radiology, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
Zhen-An HwangDepartment of Radiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, Republic of China.
Ping-Ying ChangSchool of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Hsuan-Hwai LinSchool of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Yu-Lueng ShihSchool of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Wei-Chou ChangDepartment of Radiology, Tri-Service General Hospital, Taipei, Taiwan, Republic of China. weichou.chang@gmail.com.
Guo-Shu HuangDepartment of Radiology, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
Hsian-He HsuDepartment of Radiology, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
Tri-Service General Hospital · TWNational Defense Medical Center · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-eluting microsphere transarterial chemoembolization (DEM-TACE) has been introduced to ensure more sustained and tumor-selective drug delivery for permanent embolization of HCC. The aim of this study was to determine the imaging characteristics that related to favourable treatment response in BCLC-C HCC patients treated with DEM-TACE. In total, 64 patients with BCLC-C HCC that treated with DEM-TACE using doxorubicin-eluted microspheres were retrospectively included. The images were assessed at baseline and at 4-12 weeks follow-up after receiving DEM-TACE. Pre- and post-procedural imaging characteristics were analysed by two independent radiologists and treatment response was evaluated using the modified Response Evaluation Criteria in Solid Tumors criteria. Multivariate analysis showed that vascular lake phenomenon (OR = 5.94, p = 0.03*), and homogeneous tumor enhancement (HTE) on cone-beam computed tomography (CBCT) during angiography (OR = 11.66, p < 0.001*) are associated with better radiological response. In contrast, residual tumor blush (OR = 0.11, p < 0.001*) is associated with worse radiological response. In conclusion, the initial tumor burden <50% (p = 0.012*) and HTE on CBCT (p = 0.040*) are good predictors for locoregional tumor control in patients with advanced HCCs, which can potentially improve patients' outcome.

Indexed as

Drug Delivery SystemsMicrospheresAgedCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyFemaleHumansLiver NeoplasmsMaleMiddle Aged

Identifiers

PMID31882969
PMCPMC6934464
OpenAlexW2998310875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.